Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing May 7, 2026 9:30 AM ...
A clinical trial conducted in Tanzania and Mozambique and published in The Lancet Infectious Diseases concludes that expanding the use of molecular diagnostic tests on urine and stool samples, in ...
Newly FDA-approved DOR/ISL offers an INSTI-free, 2-drug HIV treatment option with durable suppression and favorable safety. AJMC: This regimen is the first nonintegrase inhibitor 2-drug combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results